Cell-Free DNA Screening: Complexities and Challenges of Clinical Implementation

Area of Science:

• Genetics and Genomics
• Maternal-Fetal Medicine
• Clinical Diagnostics

Background:

• Cell-free DNA (cfDNA) screening for fetal aneuploidy has seen widespread adoption since 2011.
• This technology demonstrates high sensitivity and specificity in high-risk pregnancies and improved detection over traditional methods in low-risk groups.
• Increased cfDNA screening has led to a reduction in invasive diagnostic procedures like amniocentesis.

Purpose of the Study:

• To review the complexities and clinical implementation challenges of cell-free DNA screening for fetal aneuploidy.
• To provide practicing obstetricians with a summary of current cfDNA screening capabilities and limitations.
• To address emerging screening applications, including microdeletion and whole genome screening.

Main Methods:

• Review of clinical trial data and published literature on cell-free DNA screening performance.
• Analysis of implementation challenges, including test failures, accuracy in different populations, and predictive values.
• Examination of expanded screening panels beyond common aneuploidies.

Main Results:

• Cell-free DNA screening shows high accuracy for common aneuploidies, particularly in high-risk populations.
• Performance in low-risk populations is improved compared to serum screening, but positive predictive values can be limited.
• Clinical implementation is complicated by test failures, false results, and the need for careful interpretation.

Conclusions:

• Cell-free DNA screening is a valuable tool, but understanding its limitations is crucial for effective clinical use.
• Practicing obstetricians must be aware of potential challenges, including false positives/negatives and maternal health implications.
• The expansion of cfDNA screening necessitates ongoing education and careful integration into obstetric practice.